Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and Atezolizumab in MDS or CMML
NCT02935361Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Nov 2016
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine, atezolizumab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Southern California. Started Nov 2016; status: active, not recruiting.
02
Drugs
guadecitabineatezolizumab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02935361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935361.